# BIOVENTUS INC. (BVS) FY2026 Q2 P&L / Income Statement

- Company: BIOVENTUS INC. (BVS)
- Period: 2026-03-29 to 2026-06-27
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001665988-26-000042
- Page: https://plicit.ai/financials/bvs/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/bvs-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2026-03-29 through 2026-06-27. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net sales**: 153,208,000 US dollars
- **Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively)**: 47,542,000 US dollars
- **Gross profit**: 105,666,000 US dollars
- **Operating costs, net of other operating income (calculated)**: 86,539,000 US dollars
- **Operating income**: 19,127,000 US dollars
- **Other expense**: negative 3,819,000 US dollars
- **Income before income taxes**: 15,308,000 US dollars
- **Income tax (benefit) expense, net**: negative 20,897,000 US dollars
- **Net income**: 36,205,000 US dollars
- **Pain Treatments - UNITED STATES**: 72,704,000 US dollars
- **Pain Treatments - International**: 9,044,000 US dollars
- **Restorative Therapies - UNITED STATES**: 18,176,000 US dollars
- **Restorative Therapies - International**: 2,932,000 US dollars
- **Surgical Solutions - UNITED STATES**: 43,585,000 US dollars
- **Surgical Solutions - International**: 6,767,000 US dollars
- **Selling, general and administrative expense**: 82,740,000 US dollars
- **Research and development expense**: 3,173,000 US dollars
- **Restructuring costs**: negative 415,000 US dollars
- **Depreciation and amortization**: 1,041,000 US dollars
- **Loss on disposals**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BIOVENTUS INC.: $33.44 M; to noncontrolling interests: $2.76 M.

## Chart details: Revenue by Business Segment

- Page: https://plicit.ai/financials/bvs/fy2026-q2-income-statement/revenue-by-business-segment
- Chart image: https://plicit.ai/charts/bvs-fy2026-q2-revenue-by-business-segment-sankey.png

Income statement for 2026-03-29 through 2026-06-27. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net sales**: 153,208,000 US dollars
- **Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively)**: 47,542,000 US dollars
- **Gross profit**: 105,666,000 US dollars
- **Operating costs, net of other operating income (calculated)**: 86,539,000 US dollars
- **Operating income**: 19,127,000 US dollars
- **Other expense**: negative 3,819,000 US dollars
- **Income before income taxes**: 15,308,000 US dollars
- **Income tax (benefit) expense, net**: negative 20,897,000 US dollars
- **Net income**: 36,205,000 US dollars
- **US Segment**: 134,465,000 US dollars
- **International Segment**: 18,743,000 US dollars
- **Selling, general and administrative expense**: 82,740,000 US dollars
- **Research and development expense**: 3,173,000 US dollars
- **Restructuring costs**: negative 415,000 US dollars
- **Depreciation and amortization**: 1,041,000 US dollars
- **Loss on disposals**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BIOVENTUS INC.: $33.44 M; to noncontrolling interests: $2.76 M.

## Chart details: Revenue by Geography

- Page: https://plicit.ai/financials/bvs/fy2026-q2-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/bvs-fy2026-q2-revenue-by-geography-sankey.png

Income statement for 2026-03-29 through 2026-06-27. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net sales**: 153,208,000 US dollars
- **Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively)**: 47,542,000 US dollars
- **Gross profit**: 105,666,000 US dollars
- **Operating costs, net of other operating income (calculated)**: 86,539,000 US dollars
- **Operating income**: 19,127,000 US dollars
- **Other expense**: negative 3,819,000 US dollars
- **Income before income taxes**: 15,308,000 US dollars
- **Income tax (benefit) expense, net**: negative 20,897,000 US dollars
- **Net income**: 36,205,000 US dollars
- **UNITED STATES**: 134,465,000 US dollars
- **International**: 18,743,000 US dollars
- **Selling, general and administrative expense**: 82,740,000 US dollars
- **Research and development expense**: 3,173,000 US dollars
- **Restructuring costs**: negative 415,000 US dollars
- **Depreciation and amortization**: 1,041,000 US dollars
- **Loss on disposals**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BIOVENTUS INC.: $33.44 M; to noncontrolling interests: $2.76 M.